Lachgas (Nitrous Oxide)

Nitrous oxide works by diffusing into the bloodstream after inhalation and antagonizing NMDA receptors while modulating opioid pathways. This combination reduces neuronal excitability, interrupts pain signal transmission, and produces central nervous system depression, resulting in analgesia and mild sedation.

The dose of Lachgas is individualized and set by the prescribing clinician. The prescriber selects the concentration and duration based on the specific procedure, patient characteristics, and desired level of analgesia or sedation, following established clinical guidelines and safety monitoring protocols.

Safety data for nitrous oxide in pregnancy are limited, and its use should be considered only when the expected benefit justifies any potential risk to the fetus. During breastfeeding, nitrous oxide is rapidly eliminated and is generally regarded as low risk, but clinicians should evaluate each case individually.

To order Lachgas, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India serves hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with other inhalational agents such as sevoflurane or desflurane, nitrous oxide provides rapid onset and offset of analgesia with minimal cardiovascular depression. It is less potent than volatile anesthetics, making it suitable for mild to moderate sedation, whereas agents like sevoflurane are typically used for deeper general anesthesia.

Lachgas cylinders should be stored at ambient temperature, kept upright, and protected from heat, direct sunlight and physical damage. Ensure cylinders are secured to prevent tipping, and follow local regulations for medical gas storage and transport. Regularly inspect for leaks and maintain proper ventilation in storage areas.

Lachgas is delivered via a calibrated inhalation system, such as a demand valve or a face mask, allowing the patient to inhale the gas mixed with oxygen. The clinician adjusts the nitrous oxide concentration, monitors the patient’s vital signs, and ensures adequate oxygenation throughout the procedure.

The most serious risks include hypoxia from displacement of oxygen, severe respiratory depression that may require assisted ventilation, and rare neurotoxic effects such as vitamin B12 deficiency with prolonged exposure. Prompt recognition and monitoring are essential to mitigate these potentially life‑threatening complications.

Lachgas should be avoided in patients with untreated pneumothorax, severe chronic obstructive pulmonary disease, recent middle‑ear surgery, or known hypersensitivity to nitrous oxide. Caution is also advised for individuals with impaired vitamin B12 metabolism or those receiving medications that interfere with B12 utilization.